1. Home
  2. CYTK vs GGAL Comparison

CYTK vs GGAL Comparison

Compare CYTK & GGAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

N/A

Current Price

$75.87

Market Cap

10.7B

Sector

Health Care

ML Signal

N/A

Logo Grupo Financiero Galicia S.A.

GGAL

Grupo Financiero Galicia S.A.

HOLD

Current Price

$43.42

Market Cap

8.6B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYTK
GGAL
Founded
1997
1905
Country
United States
Argentina
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Commercial Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
10.7B
8.6B
IPO Year
2004
2001

Fundamental Metrics

Financial Performance
Metric
CYTK
GGAL
Price
$75.87
$43.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
19
4
Target Price
$89.26
$69.00
AVG Volume (30 Days)
1.8M
750.4K
Earning Date
05-05-2026
03-07-2023
Dividend Yield
N/A
3.70%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,368,000.00
N/A
Revenue This Year
$7.37
$62.29
Revenue Next Year
$310.19
$22.88
P/E Ratio
N/A
$13.36
Revenue Growth
N/A
N/A
52 Week Low
$35.22
$25.89
52 Week High
$88.31
$62.11

Technical Indicators

Market Signals
Indicator
CYTK
GGAL
Relative Strength Index (RSI) 41.75 35.45
Support Level $73.95 $42.83
Resistance Level $80.65 $45.01
Average True Range (ATR) 2.94 1.93
MACD -0.58 -0.57
Stochastic Oscillator 26.45 5.34

Price Performance

Historical Comparison
CYTK
GGAL

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About GGAL Grupo Financiero Galicia S.A.

Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. The company generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.

Share on Social Networks: